Standard Family Office’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Standard Family Office’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-924	Closed	-$57K	–	491
2022 Q3	$57K	Hold	924	–	–	0.03%	116
2022 Q2	$74K	Buy	+924	New	+$87.5K	0.73%	41
2022 Q1	–	Sell	-1,235	Closed	-$133K	–	265
2021 Q4	$133K	Buy	+1,235	New	+$135K	1.18%	23
2021 Q3	–	Sell	-1,553	Closed	-$145K	–	564
2021 Q2	$145K	Hold	1,553	–	–	0.03%	179
2021 Q1	$143K	Hold	1,553	–	–	0.03%	156
2020 Q4	$114K	Buy	+1,553	New	+$115K	0.03%	184

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Standard Family Office's HZNP Position: Q4 2022 in Review

Standard Family Office sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2022, closing a stake of 924 shares — an estimated $57K sold.

Standard Family Office first reported a position in HZNP in Q4 2020 and held it in 6 quarters. The position peaked at $145K in Q2 2021. 615 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

Standard Family Office reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Standard Family Office sold 924 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2022, an estimated $57K.
Standard Family Office first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2020 and held it in 6 quarters.
Standard Family Office's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $145K in Q2 2021.
615 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on Standard Family Office's 13F filing for Q4 2022, filed 13 Feb 2023.